Overview

Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)

Details

Lead Sponsor:

GlaxoSmithKline